Navigation Links
Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor
Date:6/22/2010

Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of Highly Automated QT evaluation as well as controlling for autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac’s services are supported by the COMPAS technology platform which maximizes the precision and decreases the cost of cardiac safety assessment from First-in-Human studies to Phase III studies. This suite of tools, which complies with the FDA’s ICH E14 QT/QTc guidance for Through QT Studies (TQT), was originally developed and validated at the University of Rochester’s Heart Research Follow Up Program (HRFUP), as well as in Pfizer’s Research and Development programs. iCardiac’s analytics have been used for over a decade in support of clinical trials. For more information, visit www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4164084.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. IGEN Networks Corp. announces new Board member and the cancellation of three million shares for return to treasury
2. Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang
3. Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral Metabolism Practice Patterns Around the Globe
4. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
5. Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement
6. Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project
7. Laureate Pharma Welcomes Three New Members to Business Development Team
8. ViroPharma to Present at Three November Healthcare Conferences
9. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
10. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
11. Virginia Now Owns Three Top National Business Rankings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering ... credentialing course to local area veterinarians. , The tour and course will be given ... no charge) at VetStem’s Poway facility. Staff members are welcome to attend with their ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... PARK, N.C., July 28, 2015  United Therapeutics Corporation ... results for the second quarter ended June 30, 2015. ... as compared to the second quarter of 2014 ... Jeffs, Ph.D., United Therapeutics, President and Co-Chief Executive ... to an increase in the number of patients ...
(Date:7/27/2015)... CHICAGO and FRANKLIN, Tenn. ... Inc. ("Capella"), a privately-owned  premier provider of health care ... companies in the U.S., today announced that its ... has signed a definitive agreement with Medical Properties ... the acquisition of Capella for $900 million in cash.  The ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... SPEX ) reported that the Nasdaq Stock Market ... common stock from the Nasdaq,Global Market to the Nasdaq ... on the Nasdaq Capital Market on November 11, 2008., ... market tier designations for,Nasdaq-listed stocks, and presently includes over ...
... Company Will Host a Conference Call Today To Discuss the Data ... ... (Nasdaq: SGMO ) announced today top-line data from its,SB-509-601 clinical ... Therapeutic(TM) program to develop SB-509 for diabetic,neuropathy (DN). The data demonstrate ...
... 10 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality,pharmaceutical grade glucose products in China, ... the three months ended September 30, 2008,after the ... 13, 2008.,Management will conduct a conference call on ...
Cached Biology Technology:Spherix Transfers Stock Listing to Nasdaq Capital Market 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/8/2015)... , July 8, 2015 The consumer ... this summer,s must have products such as wearables, smart wallets ... popularity for biometrics based devices continues to rapidly grow.  Biometrics ... (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ), ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and Baidu ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... termites use vibrations to choose the wood they eat ... in homes and also may provide insights into the ... most noise but have some signals that trigger attention ... entomologist Theo Evans says laboratory experiments have found that ...
... A team of Fox Chase Cancer Center scientists led ... genetic mutation that keeps a mouse strain from developing ... The report by Kappes and his colleagues appears in ... first discovered the mice with this naturally occurring defect ...
... 2,or ACC2, appears to turn the adipose or fat ... the animals can eat more and weigh less,than their ... appears online today in the Proceedings of the National,Academy ... mice bred to lack ACC2," said Dr. Salih,Wakil, chair ...
Cached Biology News:Termites feed through good vibrations 2Fox Chase Cancer Center scientists identify immune-system mutation 2Lack of enzyme turns fat cells into fat burners 2